FDA Warning Letter to OrderlyMeds Cites Logo-Branded Compounded GLP-1 Labels and "FDA-Licensed Pharmacy" Claim
On June 8, 2026, FDA issued a warning letter to OrderlyMeds after a March 2026 review of orderlymeds.com, which offers compounded semaglutide and tirzepatide products. FDA says compounded semaglutide and tirzepatide products on the site feature OrderlyMeds’ logo on the pictured label, "suggesting OrderlyMeds is the compounder of those drugs when in fact it is not," and that sourcing claims citing an "FDA-licensed pharmacy" are "false and misleading" because FDA grants no such designation. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗